Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

The key to Sanofi becoming a pure biopharma player: investment. A year later, the French company announced the divestment of ...

Adults in their 30s are at risk of developing metabolic-associated fatty liver disease (MAFLD) due to metabolic changes in ...

Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Q3 Non-GAAP EPS of €2.25. Revenue of €13.44B (+12.3%) Q3 sales growth of 15.7% at CER and business EPS of €2.86; 2024 business ...